Literature DB >> 2900132

Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man.

P W de Leeuw1, P N van Es, H A de Bruyn, W H Birkenhäger.   

Abstract

In order to evaluate the acute effects of urapidil on renal vascular tone and on pressor systems we performed a randomised placebo-controlled crossover study in 8 patients with uncomplicated essential hypertension. Each subject received, on two separate days one week apart, an intravenous injection of either placebo or urapidil (25 mg, to be increased to 50 mg if blood pressure did not fall within 5 minutes). Before and following this injection we measured blood pressure and heart rate (Dinamap), renal plasma flow (125I-hippuran), renin, angiotensin II, aldosterone, and catecholamines. The results show that urapidil, when compared to placebo, significantly reduced blood pressure, while increasing heart rate, renal blood flow, noradrenaline and adrenaline. Dopamine levels, on the other hand, were suppressed. While renin and angiotensin II were only mildly stimulated, aldosterone levels increased markedly. It is concluded that urapidil, given intravenously, has an immediate blood pressure lowering effect associated with a fall in renal vascular tone and an increase in renal perfusion. As a consequence both the sympathetic system and the renin-angiotensin system are stimulated, although the latter only to a mild degree. The rise in aldosterone may be related to withdrawal of dopaminergic tone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900132     DOI: 10.2165/00003495-198800356-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  7 in total

1.  Immediate hemodynamic effects of urapidil in patients with essential hypertension.

Authors:  I Kobrin; C Amodeo; H O Ventura; F H Messerli; E D Frohlich
Journal:  Am J Cardiol       Date:  1985-03-01       Impact factor: 2.778

2.  Post-synaptic alpha-blockade and brachial artery compliance in essential hypertension.

Authors:  J Levenson; A C Simon; J D Bouthier; A Benetos; M E Safar
Journal:  J Hypertens       Date:  1984-02       Impact factor: 4.844

3.  Comparative effects of urapidil, prazosin, and clonidine on ligand binding to central nervous system receptors, arterial pressure, and heart rate in experimental animals.

Authors:  K J Kellar; J A Quest; A C Spera; A Buller; A Conforti; J Dias Souza; R A Gillis
Journal:  Am J Med       Date:  1984-10-05       Impact factor: 4.965

4.  Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects.

Authors:  P W de Leeuw; R P Hoogma; G A van Soest; P T Tchang; W H Birkenhäger
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

5.  Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.

Authors:  R M Carey; M O Thorner; E M Ortt
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

6.  Effects of urapidil on blood pressure and adrenoceptors in various animal models.

Authors:  P A van Zwieten; M J Mathy; M J Thoolent; B Wilffert; A de Jonge; P B Timmermans
Journal:  J Hypertens Suppl       Date:  1984-12

7.  Dynamic responses to intravenous urapidil and dihydralazine in normal subjects.

Authors:  G G Belz; J H Matthews; D Graf; H C Stern; R Bachmann; G Belz; V W Steinijans; D Palm
Journal:  Clin Pharmacol Ther       Date:  1985-01       Impact factor: 6.875

  7 in total
  3 in total

1.  Biochemical effects of urapidil on red cell membrane ion transport systems in a population of elderly essential hypertensives.

Authors:  R Antonicelli; E Balducci; G Lipponi; C Lucantoni; R Gaetti; E Paciaroni
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 2.  Haemodynamic effects of the multiple action antihypertensive drug urapidil.

Authors:  G Mancia
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Urapidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H D Langtry; G J Mammen; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.